|
|
CANNABIS PRICING ANALYSIS SHOWS COMMODITIZATION IN FULLY LEGALIZED STATES |
||||||||||||||||
We analyze cannabis prices in 35 legal state markets in the U.S. to understand how age of legalization affects prices, the difference between fully legalized and medical only states, and the impact on pricing of prevalence rate, dispensary density, and market size. We also present a ranking of states to identify pricing leaders and laggards. – Takeaway #1: Cannabis prices tend to fall as fully legalized states mature, reflecting commoditization of marijuana; medical only states are relatively unaffected. Our analysis shows that the average cannabis price in older recreational markets like NV, MA, MI, CA, OR, AK, WA, and CO, with a legalization age of five+ years, stood at $249/oz on April 5. This is ~15% lower than the $290/oz average for newly legalized recreational states such as VA, NY, NM, CT, NJ, MT, and AZ, which have a legalization age of less than three years. On the other hand, states that have legalized only medical marijuana have seen average cannabis prices remain stable around the $300/oz mark. The average cannabis price in older medical states (AR, FL, ND, OH, PA, LA, MD, MN, NH, DE, RI, and HI) is almost ~$50/oz higher than the average price in the older recreational markets listed above, suggesting that medical cannabis does not lend itself to commoditization the same way as adult-use cannabis does. – Takeaway #2: Commoditization is also visible at a regional level, with early adopter states in the West having lower prices vs. relatively late entrants from the Northeast and Midwest. Western states (WA, CO, CA, and NV) took the lead in legalizing recreational marijuana (starting 2012) and are now on the lower end of the cannabis pricing spectrum, with an average price of ~$250/oz. On the other hand, states in the Midwest (IA, MN, MO, ND, OH) and Northeast (NH, RI, PA) – which are either medical only, in the process of legalizing recreational cannabis, or have recently embraced full legalization – boast average prices of ~$311/oz and ~$303/oz, respectively. – Takeaway #3: Prevalence rate and dispensary density are the other key factors that impact pricing. Our analysis shows that states with high marijuana prevalence rates have lower cannabis pricing vs. those with lower prevalence rates. For instance, OR, which has the highest marijuana prevalence rate across all states at 26%, has an average price of $198.5/oz vs. UT, which has the lowest prevalence rate at 8% but enjoys an average price of $262/oz. We also see that pricing is inversely proportional to dispensary density. States with 120+ dispensaries per million people – like OR, AL, PA, NV, and CO – have an average cannabis price of ~$259/oz. On the other hand, states that have <120 dispensaries per million people – such as NY, CA, IL, OK, NM, LA, WA, etc. – have an average price of ~$292/oz. Overall, we find that as prevalence rate and dispensary density increase, cannabis prices tend to fall, driven by a surge in retail stores and higher cannabis supply. – Takeaway #4: Bigger cannabis markets exhibit lower marijuana prices compared to their smaller peers. The average price in large markets with over $1 billion in annual legal cannabis sales, such as CA, CO, FL, etc. is $265/oz. This is much lower than the ~$309/oz average price in smaller markets such as UT, NH, VA, etc. that had less than $100 million in legal sales in 2021. We believe this difference is primarily due to a combination of three factors – age of legalization, prevalence rate, and dispensary density – and reinforces our views above. – Takeaway #5: Consumers in VA, IL, NJ, ND, IA, and MD are paying more for their stash of cannabis, while those in OR, WA, CO, UT, FL, and RI are enjoying lower prices. Fully legalized states where marijuana is sold at higher prices include VA, IL, and NJ – these are the three pricing leaders with average prices of $542/oz, $326/oz, and $323/oz, respectively. Among medical only states, the three leading markets are ND, IA, and MD where consumers are paying $354/oz, $334/oz, and $321/oz, respectively. OR, WA, and CO are the fully legalized markets on the lower end of the pricing spectrum, with average prices of $198.5/oz, ~$216/oz, and ~$221/oz, respectively. UT, FL, and RI are the states where medical cannabis users are paying less compared to consumers in other states. The average price in these three states stands at $262/oz, $264/oz, and $281/oz, respectively.
Source: Intro-act, Price of Weed. Cannabis Pricing Data as of April 5, 2022.
Source: Intro-act, Price of Weed. Cannabis Pricing Data as of April 5, 2022.
Source: Intro-act, Price of Weed. Cannabis Pricing Data as of April 5, 2022.
Source: Intro-act, Price of Weed. Cannabis Pricing Data as of April 5, 2022.
Source: Intro-act, Price of Weed. Cannabis Pricing Data as of April 5, 2022.
Source: Intro-act, Price of Weed. Cannabis Pricing Data as of April 5, 2022.
Source: Intro-act, Price of Weed. Cannabis Pricing Data as of April 5, 2022.
Source: Intro-act, Price of Weed. Cannabis Pricing Data as of April 5, 2022. |
Chart 9: Medical Only States: Average Cannabis Price ($/Oz) |
|
Source:
Intro-act, Price of Weed. Cannabis Pricing Data as of April 5, 2022.
|
CANNA EVENTS CALENDAR
Chart 44: Cannabis Company Events Calendar – Upcoming Conference Calls |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Source: Intro-act, New Cannabis Ventures
Chart 45: Cannabis Company Events Calendar – Recent Conference Calls |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Source: Intro-act, New Cannabis Ventures
Chart 46: Cannabis IPO Pipeline |
|||||||||||||||||||||||||||||||||||||||||||||
|
Source: Intro-act, New Cannabis Ventures
Chart 47: Cannabis SPAC Pipeline |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Source: Intro-act, New Cannabis Ventures
Chart 48: Cannabis Industry Events Calendar |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Source: Intro-act, Cannabis Business Times
COMPARABLES & COMPANY PROFILE LINKS
|
|
|
Share Price |
Mkt Cap (Mns) |
Ent Val (Mns) |
Price Performance |
Sales |
EBITDA |
Book Value |
||||||||
|
|
4/12/2022 |
% to High |
% to Low |
% YTD |
LTM |
NTM |
EV/Sales |
LTM |
NTM |
EV/ EBITDA |
Book/ Share |
P/ |
||||
Peer Set |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||
Canadian LP - Cultivation, Processing (and Dispensing) |
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
1 |
TLRY |
6.23 |
2,995 |
3,482 |
270% |
-23% |
-11% |
532 |
662 |
5.3 x |
39 |
68 |
51.5 x |
9.63 |
0.6 x |
||
2 |
CGC |
6.78 |
2,669 |
2,900 |
335% |
-17% |
-22% |
449 |
455 |
6.4 x |
(312) |
(164) |
- |
8.31 |
0.8 x |
||
3 |
ACB |
3.58 |
769 |
792 |
197% |
-19% |
-34% |
185 |
184 |
4.3 x |
(52) |
(13) |
- |
7.80 |
0.5 x |
||
4 |
CRON |
3.39 |
1,271 |
273 |
178% |
-13% |
-14% |
74 |
123 |
2.2 x |
(162) |
(116) |
- |
3.57 |
1.0 x |
||
5 |
HEXO |
0.54 |
221 |
396 |
1287% |
-15% |
-22% |
131 |
181 |
2.2 x |
(33) |
3 |
143.2 x |
0.96 |
0.6 x |
||
6 |
SNDL |
0.57 |
1,172 |
201 |
162% |
-30% |
44% |
38 |
387 |
0.5 x |
6 |
30 |
6.8 x |
0.53 |
1.1 x |
||
7 |
OGI |
1.65 |
513 |
388 |
113% |
-23% |
-6% |
85 |
127 |
3.1 x |
(16) |
2 |
247.0 x |
1.25 |
1.3 x |
||
8 |
CBWTF |
0.12 |
106 |
239 |
192% |
-100% |
-15% |
84 |
143 |
1.7 x |
(14) |
(5) |
- |
0.20 |
0.6 x |
||
9 |
CNTMF |
0.28 |
62 |
113 |
382% |
-14% |
-58% |
62 |
112 |
1.0 x |
17 |
33 |
3.4 x |
0.26 |
1.1 x |
||
10 |
FLGC |
1.65 |
106 |
87 |
1200% |
-21% |
-7% |
12 |
54 |
1.6 x |
(3) |
6 |
14.8 x |
0.58 |
2.9 x |
||
11 |
ALEAF |
0.09 |
28 |
65 |
540% |
-40% |
-16% |
36 |
61 |
1.1 x |
(23) |
(6) |
- |
0.03 |
2.6 x |
||
12 |
ROMJF |
1.04 |
58 |
57 |
168% |
-16% |
-31% |
21 |
40 |
1.4 x |
(11) |
2 |
37.8 x |
0.56 |
1.9 x |
||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Share Price |
Mkt Cap (Mns) |
Ent Val (Mns) |
Price Performance |
Sales |
EBITDA |
Book Value |
||||||||
|
|
|
% to High |
% to Low |
% YTD |
LTM |
NTM |
EV/Sales |
LTM |
NTM |
EV/ EBITDA |
Book/ Share |
P/ |
||||
13 |
ETRGF |
0.06 |
19 |
70 |
424% |
-18% |
-7% |
37 |
(45) |
0.18 |
0.3 x |
||||||
14 |
TGODF |
0.09 |
68 |
86 |
345% |
-23% |
22% |
39 |
57 |
1.5 x |
(16) |
(3) |
- |
0.15 |
0.6 x |
||
15 |
ETRGF |
0.06 |
19 |
70 |
424% |
-18% |
-7% |
37 |
(45) |
0.18 |
0.3 x |
||||||
16 |
FLWPF |
0.06 |
26 |
67 |
355% |
-39% |
40% |
0.17 |
0.4 x |
||||||||
17 |
VVCIF |
0.06 |
20 |
16 |
156% |
-15% |
-7% |
0.18 |
0.3 x |
||||||||
18 |
REZN-CA |
0.01 |
2 |
1 |
942% |
-51% |
-33% |
0.00 |
1.7 x |
||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US - Cultivation, Processing (and Dispensing) - MSO & SSO |
|
|
|
|
|
|
|
|
|
|
|
|
|||||
19 |
CURLF |
6.61 |
4,069 |
5,267 |
134% |
-19% |
-27% |
1,210 |
1,458 |
3.6 x |
298 |
398 |
13.2 x |
2.38 |
2.8 x |
||
20 |
GTBIF |
16.40 |
3,334 |
4,064 |
114% |
-10% |
-26% |
894 |
1,073 |
3.8 x |
308 |
354 |
11.5 x |
6.92 |
2.4 x |
||
21 |
TCNNF |
18.77 |
2,533 |
3,672 |
134% |
-10% |
-28% |
938 |
1,345 |
2.7 x |
385 |
469 |
7.8 x |
11.89 |
1.6 x |
||
22 |
VRNOF |
8.70 |
1,754 |
2,903 |
143% |
-2% |
-31% |
753 |
1,065 |
2.7 x |
357 |
492 |
5.9 x |
5.39 |
1.6 x |
||
23 |
CRLBF |
5.51 |
1,395 |
2,281 |
148% |
-6% |
-17% |
822 |
938 |
2.4 x |
194 |
257 |
8.9 x |
1.98 |
2.8 x |
||
24 |
CCHWF |
2.68 |
967 |
1,286 |
160% |
-9% |
-6% |
474 |
637 |
2.0 x |
78 |
124 |
10.4 x |
1.52 |
1.8 x |
||
25 |
AYRWF |
10.92 |
608 |
1,058 |
192% |
0% |
-28% |
358 |
602 |
1.8 x |
98 |
167 |
6.3 x |
15.26 |
0.7 x |
||
26 |
TRSSF |
5.54 |
1,395 |
1,538 |
117% |
-17% |
-9% |
210 |
390 |
3.9 x |
69 |
109 |
14.1 x |
1.17 |
4.7 x |
||
|
|
|
Share Price |
Mkt Cap (Mns) |
Ent Val (Mns) |
Price Performance |
Sales |
EBITDA |
Book Value |
||||||||
|
|
|
% to High |
% to Low |
% YTD |
LTM |
NTM |
EV/Sales |
LTM |
NTM |
EV/ EBITDA |
Book/ Share |
P/ |
||||
27 |
AAWH |
3.64 |
631 |
928 |
334% |
-5% |
-44% |
332 |
429 |
2.2 x |
80 |
108 |
8.6 x |
1.03 |
3.5 x |
||
28 |
VFF |
4.75 |
420 |
454 |
171% |
-12% |
-26% |
268 |
325 |
1.4 x |
14 |
27 |
17.0 x |
4.63 |
1.0 x |
||
29 |
FFNTF |
0.71 |
446 |
549 |
103% |
-21% |
-30% |
133 |
143 |
3.8 x |
34 |
40 |
13.8 x |
0.09 |
8.2 x |
||
30 |
GDNSF |
1.84 |
153 |
330 |
46% |
-35% |
8% |
54 |
99 |
3.3 x |
(9) |
14 |
24.4 x |
0.34 |
5.5 x |
||
30 |
ACRHF |
1.39 |
104 |
265 |
339% |
-16% |
-17% |
2.63 |
0.5 x |
||||||||
31 |
RWBYF |
0.23 |
51 |
271 |
447% |
-1% |
-31% |
107 |
0.47 |
0.5 x |
|||||||
31 |
MRMD |
0.70 |
235 |
265 |
71% |
-43% |
-19% |
138 |
1.9 x |
45 |
5.9 x |
0.11 |
6.2 x |
||||
32 |
ITHUF |
0.12 |
21 |
233 |
251% |
-27% |
26% |
(0.13) |
-0.9 x |
||||||||
33 |
UNRV |
0.18 |
78 |
159 |
156% |
-19% |
-34% |
0.31 |
0.6 x |
||||||||
34 |
GRAMF |
1.14 |
113 |
112 |
619% |
-11% |
-17% |
173 |
189 |
0.6 x |
(65) |
(69) |
- |
0.18 |
6.5 x |
||
35 |
FLOOF |
0.04 |
18 |
103 |
652% |
-51% |
27% |
70 |
83 |
1.2 x |
(90) |
(7) |
- |
0.01 |
6.9 x |
||
36 |
DBCCF |
0.09 |
35 |
63 |
244% |
-19% |
-13% |
50 |
77 |
0.8 x |
6 |
14 |
4.6 x |
0.10 |
0.9 x |
||
37 |
BMMJ |
0.20 |
23 |
31 |
193% |
-18% |
-36% |
0.29 |
0.7 x |
||||||||
38 |
YOURF |
0.13 |
35 |
32 |
149% |
-38% |
-5% |
30 |
110 |
0.3 x |
4 |
12 |
2.7 x |
0.06 |
2.1 x |
||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Share Price |
Mkt Cap (Mns) |
Ent Val (Mns) |
Price Performance |
Sales |
EBITDA |
Book Value |
||||||||
|
|
|
% to High |
% to Low |
% YTD |
LTM |
NTM |
EV/Sales |
LTM |
NTM |
EV/ EBITDA |
Book/ Share |
P/ |
||||
Medical Cannabis |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||
39 |
JAZZ |
160.94 |
9,936 |
15,504 |
17% |
-27% |
26% |
3,094 |
3,588 |
4.3 x |
1,353 |
1,743 |
8.9 x |
64.34 |
2.5 x |
||
40 |
ARNA |
99.99 |
4,982 |
|
0% |
-54% |
-13% |
0 |
0 |
10.94 |
9.1 x |
||||||
41 |
CARA |
13.26 |
710 |
546 |
124% |
-27% |
9% |
23 |
61 |
9.0 x |
(89) |
(78) |
- |
4.25 |
3.1 x |
||
42 |
IHL-ASX |
0.34 |
417 |
402 |
61% |
-53% |
-24% |
0.01 |
28.4 x |
||||||||
43 |
DOCRF |
0.56 |
163 |
148 |
237% |
-15% |
-40% |
55 |
140 |
1.1 x |
(2) |
(1) |
- |
0.73 |
0.8 x |
||
44 |
COPHF |
0.04 |
47 |
42 |
434% |
-37% |
-34% |
0.02 |
2.2 x |
||||||||
45 |
MJNA |
0.02 |
69 |
69 |
289% |
-99% |
-2% |
0.02 |
0.9 x |
||||||||
46 |
EMD-ASX |
0.22 |
62 |
56 |
60% |
-46% |
-20% |
0.03 |
8.3 x |
||||||||
47 |
XPHYF |
0.78 |
61 |
63 |
194% |
-41% |
-8% |
0.04 |
19.6 x |
||||||||
48 |
SOLCF |
1.01 |
45 |
74 |
296% |
-1% |
-57% |
5.50 |
0.2 x |
||||||||
49 |
CRDL |
1.68 |
104 |
38 |
195% |
-27% |
-9% |
0 |
#DIV/0! |
0.97 |
1.7 x |
||||||
50 |
AQSZF |
0.06 |
8 |
8 |
204% |
-19% |
-32% |
0.01 |
4.9 x |
||||||||
51 |
CRBP |
0.41 |
51 |
(20) |
462% |
-26% |
-34% |
1 |
1 |
-30.7 x |
0.55 |
0.7 x |
|||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Share Price |
Mkt Cap (Mns) |
Ent Val (Mns) |
Price Performance |
Sales |
EBITDA |
Book Value |
||||||||
|
|
|
% to High |
% to Low |
% YTD |
LTM |
NTM |
EV/Sales |
LTM |
NTM |
EV/ EBITDA |
Book/ Share |
P/ |
||||
CBD/Hemp |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||
52 |
CWBHF |
0.98 |
142 |
149 |
398% |
-20% |
-4% |
96 |
109 |
1.4 x |
(16) |
(10) |
- |
0.90 |
1.1 x |
||
53 |
GRVI |
4.48 |
74 |
69 |
109% |
-14% |
11% |
1.80 |
2.5 x |
||||||||
54 |
EPWCF |
0.14 |
47 |
47 |
371% |
7% |
-43% |
0.01 |
12.8 x |
||||||||
55 |
BTTR |
2.88 |
85 |
66 |
238% |
-27% |
-11% |
46 |
63 |
1.0 x |
(8) |
(6) |
- |
1.99 |
1.5 x |
||
56 |
YCBD |
0.80 |
47 |
32 |
409% |
-12% |
-26% |
41 |
1.45 |
0.6 x |
|||||||
57 |
OCTHF |
0.03 |
33 |
17 |
635% |
-41% |
-83% |
0.02 |
2.0 x |
||||||||
58 |
CVSI |
0.08 |
11 |
11 |
508% |
11% |
-29% |
20 |
21 |
0.5 x |
(10) |
(5) |
- |
0.03 |
2.6 x |
||
59 |
CBDHF |
0.09 |
15 |
10 |
1909% |
-22% |
-38% |
0.14 |
0.7 x |
||||||||
60 |
IWINF |
3.41 |
4 |
12 |
47% |
-71% |
8% |
0.04 |
82.2 x |
||||||||
Downstream - Distribution/Brand/Marketing/Retail/Delivery |
|
|
|
|
|
|
|
|
|
|
|
|
|||||
61 |
TPB |
31.46 |
575 |
879 |
73% |
-8% |
-17% |
445 |
452 |
1.9 x |
108 |
107 |
8.2 x |
7.14 |
4.4 x |
||
62 |
PLNHF |
2.16 |
475 |
438 |
241% |
-13% |
-27% |
120 |
156 |
2.8 x |
19 |
33 |
13.2 x |
0.87 |
2.5 x |
||
63 |
LQSIF |
7.26 |
263 |
458 |
11% |
-36% |
32% |
726 |
3.69 |
2.0 x |
|||||||
64 |
HITI |
4.05 |
246 |
289 |
146% |
-10% |
-5% |
215 |
370 |
0.8 x |
11 |
21 |
13.9 x |
2.31 |
1.8 x |
||
65 |
NBEV |
0.49 |
71 |
78 |
451% |
-5% |
-53% |
449 |
457 |
0.2 x |
(6) |
13 |
5.9 x |
1.51 |
0.3 x |
||
|
|
|
Share Price |
Mkt Cap (Mns) |
Ent Val (Mns) |
Price Performance |
Sales |
EBITDA |
Book Value |
||||||||
|
|
|
% to High |
% to Low |
% YTD |
LTM |
NTM |
EV/Sales |
LTM |
NTM |
EV/ EBITDA |
Book/ Share |
P/ |
||||
66 |
FFLWD |
3.77 |
140 |
169 |
176% |
-16% |
-4% |
176 |
206 |
0.8 x |
9 |
8 |
20.9 x |
29.16 |
0.1 x |
||
67 |
MMNFF |
0.12 |
147 |
99 |
262% |
-23% |
-26% |
0.20 |
0.6 x |
||||||||
68 |
GNLN |
0.45 |
46 |
87 |
1264% |
-11% |
-54% |
166 |
221 |
0.4 x |
(22) |
(7) |
- |
2.05 |
0.2 x |
||
69 |
SLGWF |
0.19 |
13 |
21 |
970% |
-24% |
-48% |
41 |
0.64 |
0.3 x |
|||||||
70 |
DLTNF |
0.25 |
28 |
57 |
105% |
-22% |
9% |
62 |
0.18 |
1.4 x |
|||||||
71 |
CHALF |
0.29 |
18 |
28 |
446% |
-83% |
12% |
0.28 |
1.1 x |
||||||||
Extraction, Genetics, Canna Science, etc. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
72 |
XXII |
2.18 |
355 |
309 |
178% |
-15% |
-29% |
31 |
38 |
8.2 x |
(31) |
- |
0.41 |
5.4 x |
|||
73 |
VLNS |
1.22 |
95 |
84 |
714% |
1% |
-41% |
78 |
116 |
0.7 x |
(27) |
(36) |
- |
2.98 |
0.4 x |
||
74 |
CNVCF |
0.27 |
121 |
120 |
88% |
-44% |
-26% |
0.01 |
31.2 x |
||||||||
75 |
NEPT |
0.19 |
33 |
51 |
713% |
-3% |
-53% |
42 |
71 |
0.7 x |
(53) |
(16) |
- |
0.47 |
0.4 x |
||
76 |
HCANF |
0.24 |
7 |
28 |
3507% |
-6% |
-75% |
2.08 |
0.1 x |
||||||||
77 |
NWVCF |
0.69 |
76 |
71 |
91% |
-9% |
-10% |
25 |
41 |
1.7 x |
(1) |
4 |
19.4 x |
0.16 |
4.2 x |
||
78 |
APDN |
1.91 |
14 |
12 |
324% |
-2% |
-52% |
12 |
13 |
0.9 x |
1.12 |
1.7 x |
|||||
79 |
MEDIF |
0.11 |
29 |
2 |
346% |
-6% |
-28% |
22 |
30 |
0.1 x |
(23) |
(14) |
- |
0.24 |
0.4 x |
||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Share Price |
Mkt Cap (Mns) |
Ent Val (Mns) |
Price Performance |
Sales |
EBITDA |
Book Value |
||||||||
|
|
|
% to High |
% to Low |
% YTD |
LTM |
NTM |
EV/Sales |
LTM |
NTM |
EV/ EBITDA |
Book/ Share |
P/ |
||||
Input Materials - Nutrients, Hydroponic Equipment, etc. |
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
80 |
SMG |
113.86 |
6,329 |
9,858 |
122% |
-3% |
-29% |
4,742 |
4,746 |
2.1 x |
807 |
822 |
12.0 x |
15.12 |
7.5 x |
||
81 |
HYFM |
12.86 |
575 |
1,491 |
452% |
-3% |
-55% |
479 |
579 |
2.6 x |
47 |
63 |
23.7 x |
(3.18) |
-4.0 x |
||
82 |
GRWG |
8.06 |
489 |
454 |
608% |
-16% |
-38% |
423 |
426 |
1.1 x |
34 |
30 |
15.4 x |
6.20 |
1.3 x |
||
83 |
MBII |
0.92 |
168 |
186 |
118% |
-40% |
28% |
44 |
56 |
3.3 x |
(9) |
(3) |
- |
0.16 |
5.7 x |
||
84 |
MARY-CA |
0.18 |
8 |
7 |
457% |
-34% |
-25% |
0.03 |
5.6 x |
||||||||
Testing |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||
85 |
PMD |
6.41 |
36 |
39 |
39% |
-2% |
-9% |
2.19 |
2.9 x |
||||||||
86 |
EVIO |
0.00 |
0 |
12 |
3500% |
-50% |
-80% |
(0.00) |
0.0 x |
||||||||
87 |
FLURF |
0.03 |
3 |
0 |
1396% |
0% |
-13% |
0.05 |
0.5 x |
||||||||
Technology, Ancillary Products and Services |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
88 |
MAPS |
6.76 |
476 |
521 |
229% |
-38% |
13% |
193 |
258 |
2.0 x |
32 |
16 |
32.1 x |
0.97 |
7.0 x |
||
89 |
SLHG |
1.01 |
40 |
49 |
588% |
-29% |
-24% |
38 |
39 |
1.3 x |
(11) |
(13) |
- |
0.64 |
1.6 x |
||
90 |
KERN |
0.95 |
30 |
35 |
492% |
-2% |
-44% |
21 |
27 |
1.3 x |
(13) |
(11) |
- |
1.86 |
0.5 x |
||
91 |
NEXCF |
0.70 |
70 |
65 |
429% |
-9% |
-31% |
21 |
18 |
3.7 x |
(10) |
- |
0.21 |
3.3 x |
|||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Share Price |
Mkt Cap (Mns) |
Ent Val (Mns) |
Price Performance |
Sales |
EBITDA |
Book Value |
||||||||
|
|
|
% to High |
% to Low |
% YTD |
LTM |
NTM |
EV/Sales |
LTM |
NTM |
EV/ EBITDA |
Book/ Share |
P/ |
||||
92 |
AGFY |
3.71 |
98 |
45 |
869% |
-8% |
-60% |
60 |
140 |
0.3 x |
(20) |
(18) |
- |
6.17 |
0.6 x |
||
93 |
FORA |
4.82 |
157 |
151 |
199% |
3% |
-47% |
26 |
5.9 x |
(15) |
- |
0.79 |
6.1 x |
||||
94 |
UGRO |
8.55 |
87 |
53 |
102% |
-21% |
-18% |
62 |
111 |
0.5 x |
5 |
10.4 x |
4.49 |
1.9 x |
|||
95 |
VEXTF |
0.42 |
28 |
60 |
106% |
-22% |
-18% |
43 |
1.4 x |
15 |
3.9 x |
0.42 |
1.0 x |
||||
96 |
BLOZF |
0.48 |
55 |
47 |
167% |
-19% |
14% |
0.07 |
6.9 x |
||||||||
97 |
AUSAF |
0.08 |
22 |
26 |
332% |
-2% |
-45% |
0.16 |
0.5 x |
||||||||
Real Estate & Investors |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||
98 |
IIPR |
186.75 |
5,148 |
5,078 |
54% |
-13% |
-29% |
205 |
278 |
18.3 x |
256 |
19.9 x |
62.38 |
3.0 x |
|||
99 |
CODI |
23.79 |
1,652 |
3,386 |
40% |
-8% |
-22% |
1,992 |
2,083 |
1.6 x |
361 |
399 |
8.5 x |
11.75 |
2.0 x |
||
100 |
AFCG |
18.15 |
358 |
421 |
40% |
-1% |
-20% |
38 |
72 |
5.8 x |
72 |
5.8 x |
16.61 |
1.1 x |
|||
101 |
POWER REIT |
PW |
32.90 |
111 |
139 |
149% |
0% |
-52% |
8 |
12 |
11.6 x |
14.79 |
2.2 x |
||||
102 |
CNPOF |
1.10 |
157 |
(87) |
82% |
-18% |
-4% |
1.93 |
0.6 x |
||||||||
103 |
SILVER SPIKE INVESTMENT CORP |
SSIC |
12.65 |
113 |
136 |
22% |
-5% |
7 |
20.1 x |
(0.07) |
-189.9 x |
||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Share Price |
Mkt Cap (Mns) |
Ent Val (Mns) |
Price Performance |
Sales |
EBITDA |
Book Value |
||||||||
|
|
|
% to High |
% to Low |
% YTD |
LTM |
NTM |
EV/Sales |
LTM |
NTM |
EV/ EBITDA |
Book/ Share |
P/ |
||||
SPACs |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||
104 |
SPKC.USD-CA |
|
|
|
(0.58) |
||||||||||||
105 |
SPKBU |
9.94 |
286 |
|
5% |
-2% |
0% |
|
|||||||||
106 |
CERAF |
9.83 |
13 |
(78) |
15% |
-10% |
0% |
(0.40) |
-24.4 x |
||||||||
107 |
GNRSU |
1.89 |
33 |
33 |
605% |
0% |
-53% |
|
|||||||||
108 |
TUSCAN HOLDINGS CORP. II |
THCAU |
11.17 |
246 |
246 |
27% |
-20% |
7% |
|
||||||||
109 |
TCACU |
10.07 |
201 |
201 |
4% |
-9% |
-1% |
|
|||||||||
110 |
CHOICE CONSOLIDATION CORP |
CDXXF |
|
|
|
|
|||||||||||
111 |
MCMJ |
9.99 |
413 |
413 |
16% |
-47% |
0% |
53 |
7.8 x |
(31) |
- |
6.40 |
1.6 x |
||||
112 |
ACKIU |
10.00 |
138 |
138 |
14% |
-19% |
-3% |
|
|||||||||
113 |
BGPPF |
9.69 |
1,115 |
33 |
932% |
-100% |
4% |
(0.84) |
-11.5 x |
||||||||
114 |
CANNA-GLOBAL ACQUISITION CORP |
CNGLU |
10.12 |
233 |
|
11% |
-6% |
-4% |
|
||||||||
115 |
CLOEU |
10.23 |
141 |
|
20% |
-13% |
-2% |
|
|||||||||
116 |
NORTHERN LIGHTS ACQUISITION CORP. |
NLITU |
10.20 |
123 |
|
12% |
-3% |
0% |
|
||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Share Price |
Mkt Cap (Mns) |
Ent Val (Mns) |
Price Performance |
Sales |
EBITDA |
Book Value |
||||||||
|
|
|
% to High |
% to Low |
% YTD |
LTM |
NTM |
EV/Sales |
LTM |
NTM |
EV/ EBITDA |
Book/ Share |
P/ |
||||
Diversified |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||
117 |
MO |
54.91 |
99,786 |
123,286 |
0% |
-23% |
16% |
21,111 |
21,050 |
5.9 x |
11,832 |
12,371 |
10.0 x |
(0.88) |
-62.3 x |
||
118 |
STZ |
248.83 |
40,893 |
56,936 |
4% |
-17% |
-1% |
8,821 |
9,400 |
6.1 x |
3,268 |
3,478 |
16.4 x |
60.03 |
4.1 x |
||
119 |
INCR-TAE |
6.43 |
290 |
259 |
44% |
-13% |
-4% |
3.11 |
2.1 x |
||||||||
120 |
TLLTF |
0.27 |
90 |
194 |
115% |
-38% |
22% |
203 |
258 |
0.8 x |
22 |
29 |
6.7 x |
0.63 |
0.4 x |
||
121 |
CLVR |
1.71 |
51 |
38 |
626% |
-47% |
-38% |
15 |
23 |
1.7 x |
(25) |
(22) |
- |
2.74 |
0.6 x |
||
122 |
SHWZ |
2.09 |
96 |
96 |
41% |
-40% |
18% |
108 |
179 |
0.5 x |
42 |
2.3 x |
2.97 |
0.7 x |
|||
123 |
LOWLF |
0.33 |
33 |
76 |
371% |
-31% |
4% |
67 |
85 |
0.9 x |
(16) |
1 |
54.8 x |
0.63 |
0.5 x |
||
124 |
PCLOF |
0.55 |
75 |
73 |
182% |
-2% |
-30% |
2 |
0.12 |
4.5 x |
|||||||
125 |
KHRNF |
0.21 |
37 |
26 |
130% |
-39% |
26% |
12 |
20 |
1.3 x |
(16) |
(10) |
- |
0.24 |
0.9 x |
Important Disclosures
Analyst Certification: I, Peter Wright, certify that the views expressed in the research report accurately reflect my personal views about the subject securities or issues. I also do not receive direct or indirect compensation based on my recommendations or views. Intro-act, Inc. (Intro-act) issued this report and may seek fees for the assistance with investor targeting, access, and further investor preparation services. Intro-act, Inc. will not seek renumeration for any investment banking service or investment advice.
Accuracy of content: All information used in the publication of this report has been compiled from publicly available sources who are believed to be reliable. However, the issuer and related parties, as well as Intro-act, do not guarantee the accuracy or completeness of this report, and have not sought for this information to be independently verified. Opinions contained in this report represent those of the Intro-act analysts at the time of publication. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, and estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties, and other factors that may cause the actual results, performance, or achievements of their subject matter to be materially different from current expectations.
Exclusion of Liability: To the fullest extent allowed by law, Intro-act, Inc. shall not be liable for any direct, indirect, or consequential losses, loss of profits, damages, or costs or expenses incurred or suffered by you arising out or in connection with the access to, use of, or reliance on any information contained in this note.
No personalized advice: The information that we provide should not be construed in any manner whatsoever as personalized advice. Also, the information provided by us should not be construed by any subscriber or prospective subscriber as Intro-act’s solicitation to affect, or attempt to affect, any transaction in a security. The securities described in the report may not be eligible for sale in all jurisdictions or to certain categories of investors.
Investment in securities mentioned: Intro-act has a restrictive policy relating to personal dealing and conflicts of interest. Intro-act, Inc. does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees, and contractors of Intro-act may have a position in any or related securities mentioned in this report, subject to Intro-act’s policies on personal dealing and conflicts of interest.
Copyright: Copyright 2022 Intro-act, Inc. (Intro-act).
Intro-act is not registered as an investment adviser with the Securities and Exchange Commission. Intro-act relies upon the “publishers’ exclusion” from the definition of investment adviser under Section 202(a) (11) of the Investment Advisers Act of 1940 and corresponding state securities laws. This report is a bona fide publication of general and regular circulation offering impersonal investment-related advice, not tailored to a specific investment portfolio or the needs of current and/or prospective subscribers. As such, Intro-act does not offer or provide personal advice, and the research provided is for informational purposes only. No mention of a particular security in this report constitutes a recommendation to buy, sell, or hold that or any security, or that any particular security, portfolio of securities, transaction, or investment strategy is suitable for any specific person.